Process and outcome indicators for infection control and prevention in European acute care hospitals in 2011 to 2012-Results of the PROHIBIT study
Process and outcome indicators for infection control and prevention in European acute care hospitals in 2011 to 2012-Results of the PROHIBIT study
复制标题
DOI：
10.2807/1560-7917.es.2018.23.21.1700513
复制
发表时间：
2018-05-24
期刊：
影响因子：
19
通讯作者：
Gastmeier, Petra
中科院分区：
文献类型：
--
作者：
Hansen, Sonja;Schwab, Frank;Gastmeier, Petra
简介：来自24个欧洲国家的医院被要求提供有关感染预防和控制（IPC）指标的信息，作为通过干预和培训预防医院感染（PROHIBIT）调查的一部分。研究方法：297家建立了医疗相关感染（HCAI）监测的医院的IPC领导人员通过问卷调查提供了当地监测和反馈的信息。结果如下：大多数医院关注血流感染（BSI）（n=251）和手术部位感染（SSI）（n=254），148家医院进行了SSI出院后监测。作为HCAI监测的一部分，耐甲氧西林金黄色葡萄球菌（MRSA）是受监测的主要多重耐药微生物（MDRO）。79%的医院（n=236）监测含酒精的洗手液（ABHR）的消费。对当地IPC委员会的反馈主要包括HCAI（n=259; 87%）和HCAI中MDRO（n=245; 83%）的结局数据;因此MDRO数据的反馈取决于医院规模（p = 0.012）。讨论/结论：监测的目的和方法在欧洲各不相同，BSI、551和MRSA比肺炎和尿路感染等指标受到更多的关注，后者可能同样重要。为了在欧洲最大限度地预防和控制HCAI和MDRO，应通过针对相关HCAI进一步改善监测。应更详细地探讨反馈的作用。
Introduction: Hospitals from 24 European countries were asked for information on infection prevention and control (IPC) indicators as part of the Prevention of Hospital Infections by Intervention and Training (PROHIBIT) survey. Methods: Leading IPC personnel of 297 hospitals with established healthcare-associated infection (HCAI) surveillance provided information on local surveillance and feedback by using a questionnaire. Results: Most hospitals focused on bloodstream infection (BSI) (n=251) and surgical site infection (SSI) (n=254), with a SSI post-discharge surveillance in 148 hospitals. As part of the HCAI surveillance, meticillin-resistant Staphylococcus aureus (MRSA) was the leading multidrug-resistant organism (MDRO) under surveillance. Seventy-nine per cent of hospitals (n=236) monitored alcohol-based hand rub (ABHR) consumption. Feedback to the local IPC committees mainly included outcome data on HCAI (n=259; 87%) and MDRO among HCAI (n=245; 83%); whereupon a feedback of MDRO data depended on hospital size (p = 0.012). Discussion/conclusion: Objectives and methods of surveillance vary across Europe, with BSI, 551 and MRSA receiving considerably more attention than indicators such as pneumonia and urinary tract infection, which may be equally important. In order to maximise prevention and control of HCAI and MDRO in Europe, surveillance should be further improved by targeting relevant HCAI. The role of feedback should be explored in more detail.